“Obesity and associated metabolic syndrome have quickly become a pandemic and a major detriment to human health globally.
The presence of non-alcoholic fatty liver disease (NAFLD; hepatosteatosis) in obesity has been linked to the worsening of the metabolic syndrome, including the development of insulin resistance and cardiovascular disease. Currently, there are few options to treat NAFLD, including life style changes and insulin sensitizers.
Recent evidence suggests that the cannabinoids Δ9-tetrahydrocannabivarin (THCV) and cannabidiol (CBD) improve insulin sensitivity; we aimed at studying their effects on lipid levels…
THCV and CBD directly reduce accumulated lipid levels in vitro in a hepatosteatosis model and adipocytes.
…these cannabinoids are able to increase yolk lipid mobilization and inhibit the development of hepatosteatosis respectively.
CONCLUSIONS:
Our results suggest that THCV and CBD might be used as new therapeutic agents for the pharmacological treatment of obesity- and metabolic syndrome-related NAFLD/hepatosteatosis.”